MARKET

DYN

DYN

Dyne Therapeutics, Inc.
NASDAQ
19.27
-0.15
-0.77%
After Hours: 19.10 -0.17 -0.88% 19:36 12/12 EST
OPEN
19.51
PREV CLOSE
19.42
HIGH
19.96
LOW
19.20
VOLUME
4.45M
TURNOVER
--
52 WEEK HIGH
29.72
52 WEEK LOW
6.36
MARKET CAP
2.75B
P/E (TTM)
-5.2614
1D
5D
1M
3M
1Y
5Y
1D
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Barchart · 2d ago
Dyne Therapeutics Is Maintained at Buy by Stifel
Dow Jones · 3d ago
Stifel Maintains Buy on Dyne Therapeutics, Raises Price Target to $39
Benzinga · 3d ago
Stifel Nicolaus Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)
TipRanks · 3d ago
Dyne Therapeutics price target raised to $39 from $36 at Stifel
TipRanks · 3d ago
DYNE THERAPEUTICS INC <DYN.O>: STIFEL RAISES TARGET PRICE TO $39 FROM $36
Reuters · 3d ago
U.S. RESEARCH ROUNDUP-BioNTtech, GE Vernova, Synopsys
Reuters · 3d ago
What Dyne Therapeutics (DYN)'s DELIVER Trial Success and $350 Million Raise Mean For Shareholders
Simply Wall St · 3d ago
More
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.

Webull offers Dyne Therapeutics Inc stock information, including NASDAQ: DYN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DYN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DYN stock methods without spending real money on the virtual paper trading platform.